EFPIA concerned over SPC waiver amendments
30-11-2018
EFPIA warns that SPC waiver will weaken EU IP framework
18-10-2018
artjazz / iStockphoto.com
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has sharply criticised an opinion on supplementary protection certificate (SPC) proposals that was issued by a European Parliament committee.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
EFPIA, European Parliament, European Parliament Committee on International Trade, International Trade, Health, Pharmaceuticals, SPC manufacturing waiver
